You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

~ Buy the MAYZENT (siponimod) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR MAYZENT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for MAYZENT

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03623243 ↗	Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.	Recruiting	Novartis Pharmaceuticals	Phase 3	2019-02-14	To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
NCT04792567 ↗	Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)	Recruiting	Novartis Pharmaceuticals	Phase 4	2021-04-19	The purpose of this study is to understand whether participants can mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break.
NCT04925557 ↗	Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis	Recruiting	Robert Zivadinov, MD, PhD	Phase 4	2021-09-27	To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MAYZENT

Condition Name

Chart
Table

Condition Name for MAYZENT
Intervention	Trials
Multiple Sclerosis	1
Multiple Sclerosis, Relapsing MS, Advancing Multiple Sclerosis	1
Secondary Progressive Multiple Sclerosis	1
Secondary-progressive Multiple Sclerosis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MAYZENT
Intervention	Trials
Sclerosis	3
Multiple Sclerosis	3
Neoplasm Metastasis	2
Multiple Sclerosis, Chronic Progressive	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MAYZENT

Trials by Country

Map
Table

Trials by Country for MAYZENT
Location	Trials
United States	27
Germany	2
Puerto Rico	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MAYZENT
Location	Trials
New York	2
Missouri	1
Arizona	1
California	1
Colorado	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MAYZENT

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MAYZENT
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MAYZENT
Clinical Trial Phase	Trials
Recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MAYZENT

Sponsor Name

Chart
Table

Sponsor Name for MAYZENT
Sponsor	Trials
Novartis Pharmaceuticals	2
Robert Zivadinov, MD, PhD	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MAYZENT
Sponsor	Trials
Industry	2
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.